AUROBINDO PHARMA
Quarterly Results Analysis [Jun2024]
AUROBINDO PHARMA Quarterly Results
Consolidated | Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹7,567 Cr | ₹7,580 Cr | ₹7,352 Cr | ₹7,219 Cr | ₹6,851 Cr | ₹6,473 Cr | ₹6,407 Cr | ₹5,739 Cr |
Expenses | ₹5,947 Cr | ₹5,907 Cr | ₹5,750 Cr | ₹5,846 Cr | ₹5,699 Cr | ₹5,471 Cr | ₹5,453 Cr | ₹4,949 Cr |
Operating Income | ₹1,620 Cr | ₹1,673 Cr | ₹1,601 Cr | ₹1,373 Cr | ₹1,151 Cr | ₹1,002 Cr | ₹954 Cr | ₹791 Cr |
Other Income | ₹221 Cr | ₹136 Cr | ₹163 Cr | ₹187 Cr | ₹116 Cr | ₹135 Cr | ₹93 Cr | ₹57 Cr |
Interest | ₹111 Cr | ₹89 Cr | ₹76 Cr | ₹68 Cr | ₹57 Cr | ₹56 Cr | ₹45 Cr | ₹25 Cr |
Depreciation | ₹404 Cr | ₹354 Cr | ₹423 Cr | ₹418 Cr | ₹327 Cr | ₹346 Cr | ₹321 Cr | ₹298 Cr |
Profit Before Tax | ₹1,325 Cr | ₹1,243 Cr | ₹1,265 Cr | ₹1,075 Cr | ₹815 Cr | ₹736 Cr | ₹681 Cr | ₹525 Cr |
Profit After Tax | ₹920 Cr | ₹920 Cr | ₹943 Cr | ₹751 Cr | ₹573 Cr | ₹512 Cr | ₹492 Cr | ₹412 Cr |
EPS | ₹15.69 | ₹15.51 | ₹15.98 | ₹12.92 | ₹9.74 | ₹8.64 | ₹8.38 | ₹6.99 |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | -0.1% | -6.4% | 63.5% |
SUN PHARMACEUTICAL INDUSTRIES | -1.2% | -4.7% | 58.1% |
CIPLA | 2.7% | -2.8% | 32.8% |
DR REDDYS LABORATORIES | 2.3% | -2.2% | 20.9% |
ZYDUS LIFESCIENCES | -0.7% | -5.6% | 69.2% |
DIVIS LABORATORIES | 0.8% | 7.1% | 73.4% |
MANKIND PHARMA | 3.1% | 5.6% | 52.9% |
TORRENT PHARMACEUTICALS | 0.2% | -8.8% | 62.6% |
LUPIN | -1% | -2.3% | 83.9% |
AUROBINDO PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -0.17 % |
Y-o-Y | 10.46 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Jun2024 | ₹7,567 Cr | -0.17 | |
Mar2024 | ₹7,580 Cr | 3.11 | |
Dec2023 | ₹7,352 Cr | 1.83 | |
Sep2023 | ₹7,219 Cr | 5.38 | |
Jun2023 | ₹6,851 Cr | 5.83 | |
Mar2023 | ₹6,473 Cr | 1.03 | |
Dec2022 | ₹6,407 Cr | 11.63 | |
Sep2022 | ₹5,739 Cr | - |
AUROBINDO PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -3.18 % |
Y-o-Y | 40.66 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Jun2024 | ₹1,620 Cr | -3.18 | |
Mar2024 | ₹1,673 Cr | 4.47 | |
Dec2023 | ₹1,601 Cr | 16.59 | |
Sep2023 | ₹1,373 Cr | 19.29 | |
Jun2023 | ₹1,151 Cr | 14.89 | |
Mar2023 | ₹1,002 Cr | 5.01 | |
Dec2022 | ₹954 Cr | 20.69 | |
Sep2022 | ₹791 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -3.04 % |
Y-o-Y | 27.31 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Jun2024 | 21.4% | -3.04 | |
Mar2024 | 22.07% | 1.33 | |
Dec2023 | 21.78% | 14.51 | |
Sep2023 | 19.02% | 13.15 | |
Jun2023 | 16.81% | 8.59 | |
Mar2023 | 15.48% | 3.89 | |
Dec2022 | 14.9% | 8.13 | |
Sep2022 | 13.78% | - |
AUROBINDO PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -0.04 % |
Y-o-Y | 60.62 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Jun2024 | ₹920 Cr | -0.04 | |
Mar2024 | ₹920 Cr | -2.39 | |
Dec2023 | ₹943 Cr | 25.50 | |
Sep2023 | ₹751 Cr | 31.18 | |
Jun2023 | ₹573 Cr | 11.87 | |
Mar2023 | ₹512 Cr | 4.10 | |
Dec2022 | ₹492 Cr | 19.44 | |
Sep2022 | ₹412 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 0.08 % |
Y-o-Y | 45.33 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Jun2024 | 12.15 % | 0.08 | |
Mar2024 | 12.14 % | -5.30 | |
Dec2023 | 12.82 % | 23.27 | |
Sep2023 | 10.4 % | 24.40 | |
Jun2023 | 8.36 % | 5.69 | |
Mar2023 | 7.91 % | 3.13 | |
Dec2022 | 7.67 % | 6.97 | |
Sep2022 | 7.17 % | - |
AUROBINDO PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 1.16 % |
Y-o-Y | 61.09 % |
Quarters | EPS | % Change | |
---|---|---|---|
Jun2024 | ₹15.69 | 1.16 | |
Mar2024 | ₹15.51 | -2.94 | |
Dec2023 | ₹15.98 | 23.68 | |
Sep2023 | ₹12.92 | 32.65 | |
Jun2023 | ₹9.74 | 12.73 | |
Mar2023 | ₹8.64 | 3.10 | |
Dec2022 | ₹8.38 | 19.89 | |
Sep2022 | ₹6.99 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD